Table 1. Baseline characteristics of 70- and 120-w ThuVEP groupsa.
| 70-w ThuVEP | 120-w ThuVEP | P value | |
|---|---|---|---|
| No. of patients | 44 | 40 | |
| Age (year)b | 70.66±8.62 (46–87) | 69.50±6.15 (55–82) | 0.375 |
| PSA (ng ml−1)b | 10.68±11.05 (1.23–42.00) | 7.98±7.30 (0.51–44.25) | 0.973 |
| Prostate volume (ml) | 79.90±27.49 (60–167) | 88.53±25.10 (60–170) | 0.033 |
| IPSSb | 17.77±7.43 (7–28) | 17.60±8.53 (7–30) | 0.751 |
| QoLb | 4.71±1.07 (2–6) | 3.80±1.37 (1–6) | 0.063 |
| Qmaxb (ml s−1) | 8.18±3.15 (4.7–14.0) | 8.44±3.86 (1.3–14.4) | 0.816 |
| PVR (ml) | 110.00±55.98 (10–200) | 254.69±172.89 (20–700) | 0.000 |
| Preoperative urinary retention (%) | 31.81 | 32.50 | NS |
Abbreviations: IPSS, International Prostate Symptom Score; NS, not significant; PSA, prostate-specific antigen; PVR, postvoiding residual urine; Qmax, maximum urinary flow rate; QoL, quality of life; ThuVEP, Tm:YAG VapoEnucleation of the prostate.
a
The data are mean±s.d. (range). Differences between 70- and 120-w ThuVEP were assessed using the Mann–Whitney U test. Categorical variables were compared using the Chi-square test.
b
No statistical differences between 70- and 120-w ThuVEP.